| The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4189 | 2010 |
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers PA Steck, MA Pershouse, SA Jasser, WKA Yung, H Lin, AH Ligon, ... Nature genetics 15 (4), 356-362, 1997 | 4123 | 1997 |
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ... New England Journal of Medicine 372 (4), 311-319, 2015 | 3889 | 2015 |
| Recurrent BRAF mutations in Langerhans cell histiocytosis G Badalian-Very, JA Vergilio, BA Degar, LE MacConaill, B Brandner, ... Blood, The Journal of the American Society of Hematology 116 (11), 1919-1923, 2010 | 1212 | 2010 |
| Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis JW Locasale, AR Grassian, T Melman, CA Lyssiotis, KR Mattaini, AJ Bass, ... Nature genetics 43 (9), 869-874, 2011 | 1165 | 2011 |
| Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Journal of clinical oncology 34 (23), 2698, 2016 | 1043 | 2016 |
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016 | 994 | 2016 |
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome YJ Cho, A Tsherniak, P Tamayo, S Santagata, A Ligon, H Greulich, ... Journal of clinical oncology 29 (11), 1424, 2011 | 824 | 2011 |
| CDK8 is a colorectal cancer oncogene that regulates β-catenin activity R Firestein, AJ Bass, SY Kim, IF Dunn, SJ Silver, I Guney, E Freed, ... Nature 455 (7212), 547-551, 2008 | 791 | 2008 |
| PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome MGM Roemer, RH Advani, AH Ligon, Y Natkunam, RA Redd, H Homer, ... Journal of Clinical Oncology 34 (23), 2690, 2016 | 780 | 2016 |
| Focal gains of VEGFA and molecular classification of hepatocellular carcinoma DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, ... Cancer research 68 (16), 6779-6788, 2008 | 733 | 2008 |
| Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma U Schüller, VM Heine, J Mao, AT Kho, AK Dillon, YG Han, E Huillard, ... Cancer cell 14 (2), 123-134, 2008 | 718 | 2008 |
| Targetable genetic features of primary testicular and primary central nervous system lymphomas B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ... Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016 | 516 | 2016 |
| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 445 | 2020 |
| Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma AM Fontebasso, S Papillon-Cavanagh, J Schwartzentruber, H Nikbakht, ... Nature genetics 46 (5), 462-466, 2014 | 443 | 2014 |
| Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ... Journal of clinical oncology 28 (5), 835, 2010 | 439 | 2010 |
| Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer EP Garcia, A Minkovsky, Y Jia, MD Ducar, P Shivdasani, X Gong, ... Archives of Pathology and Laboratory Medicine 141 (6), 751-758, 2017 | 387 | 2017 |
| Integration of cytogenetic landmarks into the draft sequence of the human genome T BAC Resource Consortium, VG Cheung, N Nowak, W Jang, IR Kirsch, ... Nature 409 (6822), 953-958, 2001 | 380 | 2001 |
| Institutional implementation of clinical tumor profiling on an unselected cancer population LM Sholl, K Do, P Shivdasani, E Cerami, AM Dubuc, FC Kuo, EP Garcia, ... JCI insight 1 (19), 2016 | 378 | 2016 |
| Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, ... The lancet oncology 20 (7), 1011-1022, 2019 | 372 | 2019 |
Keith L. LigonAssociate Professor, Harvard Medical School在 dfci.harvard.edu 的電子郵件地址已通過驗證
